Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04990388 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)
A Phase 1 study, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04990388 is a Phase 1 study that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 9 participants.
The verdict
NCT04990388, a Phase 1 study, was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).
Interventions
- OTHER Placebo
- BIOLOGICAL UX053
- DRUG Antipyretic
- DRUG H2 Blocker
- DRUG H1 Blocker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04990388
The ClinicalTrials.gov registry entry for NCT04990388 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04990388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04990388 about?
NCT04990388 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)". The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).
What is the current status of trial NCT04990388?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-10-18. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT04990388?
The interventions under investigation include: Placebo (OTHER), UX053 (BIOLOGICAL), Antipyretic (DRUG), H2 Blocker (DRUG), H1 Blocker (DRUG).
Who is sponsoring clinical trial NCT04990388?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.